Yahoo Movies
‘Ellen DeGeneres Show’ loses viewers, revenue after workplace toxicity scandal
Ellen DeGeneres's talk show has taken a hit after she was accused of workplace misconduct last year, the New York Times reported Monday.
Ellen DeGeneres's talk show has taken a hit after she was accused of workplace misconduct last year, the New York Times reported Monday.
Iran sets trial dates for dual nationals before nuclear deal talks in ViennaTrials coincide with Iran announcing desire for ‘all for all’ simultaneous prisoner exchanges with west The Iranian foreign ministry spokesman, Saeed Khatibzadeh, has said a prisoner exchange would involve all dual nationals being released simultaneously. Photograph: Anadolu Agency/Getty
Coronavirus LIVE Updates: The chief minister said the EC should ensure that COVID-19 patients are able to vote in the remaining three phases of polling for state assembly elections
The S&P 500 and the Dow Jones indexes were higher on Wednesday after sliding for two straight sessions, while the Nasdaq remained muted as Netflix kicked off quarterly earnings for technology behemoths with a disappointing report. The streaming service provider tumbled 7.1% as it reported slower subscriber growth in the first quarter after a pandemic boom.
Ap19FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE KEY INFORMATION Name of person dealing (Note 1)Davidson Kempner Capital Management LP Company dealt inWillis Towers Watson PLCClass of relevant security to which the dealings being disclosed relate (Note 2)US$0.000304635 ordinary sharesDate of dealing2021-04-20 INTERESTS AND SHORT POSITIONS Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) LongShort Number (%)Number (%)(1) Relevant securities2,080,8781.61340.000.00(2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total2,080,8781.61340.000.00 Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security:LongShort Number (%)Number (%)(1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total Ap20 DEALINGS (Note 4) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 5)Purchase2,985USD 238.0411 Derivatives transactions (other than options transactions) Product name,e.g. CFDNature of transaction(Note 6)Number of relevant securities(Note 7)Price per unit(Note 5) Options transactions in respect of existing relevant securities Writing, selling, purchasing or varying Product name,e.g. call optionWriting, selling, purchasing, varying etc.Number of securities to which the option relates (Note 7)Exercise priceType, e.g. American, European etc.Expiry dateOption money paid/received per unit (Note 5) Exercising Product name,e.g. call optionNumber of securitiesExercise price per unit (Note 5) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction(Note 8)DetailsPrice per unit(if applicable) (Note 5) Ap212. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure2021-04-21Contact nameJames GangeTelephone number212 446 4029If a connected EFM, name of offeree/offeror with which connected If a connected EFM, state nature of connection (Note 10)
BIOQUAL, Inc. (OTC-Pink:BIOQ) (www.bioqual.com):
OVERLAND PARK, Kan., April 21, 2021 (GLOBE NEWSWIRE) -- Yellow Corporation (NASDAQ: YELL) is recruiting employees for new positions in Des Moines, Iowa. On Wednesday, April 28 and Thursday, April 29, Yellow will host two hiring events as the trucking company looks to fill jobs including dock workers, local drivers and box truck drivers. Yellow intends to hire qualified individuals immediately for 26 jobs in Des Moines with more positions open nationwide. Yellow is the second largest less-than-truckload carrier and the fifth largest transportation company in North America. Yellow’s 30,000 employees are based in all 50 states as well as Puerto Rico, Canada and Mexico. Yellow’s Des Moines hiring events are among more than two dozen similar recruiting events taking place across America between now and July. By the end of 2021, Yellow aims to hire thousands of new employees nationwide with at least 1,500 of those positions earmarked for commercial drivers. “Seventy percent of America’s freight moves on our nation’s highways, so it’s essential that the industry continue to ramp up hiring to keep the U.S. supply chain humming along,” said Darren Hawkins, Chief Executive Officer of Yellow. “Yellow pays very competitive wages and offers outstanding healthcare benefits for employees,” said Mr. Hawkins. “For those with trucking experience or not, or folks looking for a new opportunity or needing to make a job change due to pandemic fallout, it’s an exciting time to build a career and a future at Yellow.” “Hiring is our number one priority,” said Hawkins. “Our freight professionals serve as the economic lifeline to nearly every community in America. Transportation and trucking people are patriots.” On Wednesday, April 28 and and Thursday, April 29, Yellow’s recruiting events will take place at its Holland Des Moines terminal, 6144 Northeast 22nd Street, Des Moines, Iowa from 9:00 AM – 4:00 PM. Candidates will have the opportunity to interview with hiring managers and receive assistance with applications and paperwork. No reservation is necessary. For more information or to apply, please visit www.MyYellow.com, and click “Careers” in the top right. About Yellow CorporationYellow Corporation has one of the largest, most comprehensive logistics and less-than-truckload (LTL) networks in North America with local, regional, national, and international capabilities. Through our teams of experienced service professionals, Yellow Corporation offers industry-leading expertise in flexible supply chain solutions, ensuring customers can ship industrial, commercial, and retail goods with confidence. Yellow Corporation, headquartered in Overland Park, Kan., is the holding company for a portfolio of LTL brands including Holland, New Penn, Reddaway, and YRC Freight, as well as the logistics company HNRY Logistics. Please visit our website at www.myyellow.com for more information. Media Contacts:Mike Kelley 913-696-6121Heather Nauert mike.kelley@myyellow.com heather.nauert@myyellow.com Investor Contact:Tony Carreño 913-696-6108 investor@myyellow.com
The "Compounding Pharmacies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Oral Medications, Topical Medications, Suppositories, Others); Therapeutic Area (Pain Medications, Hormone Replacement Therapies, Dermatological Applications, Others) and Geography" report has been added to ResearchAndMarkets.com's offering.
“Loving Highsmith,” a new documentary based on the American crime novelist’s personal writings about her lovers and family, has been acquired by Filmcoopi and Salzgeber & Co fir distribution in Switzerland and Germany. Salzgeber & Co will release “Loving Highsmith” in Germany, Filmcoopi in Switzerland. The film, in post-production, was presented Sunday at a Swiss […]
MONTREAL — Metro Inc. reported a bump in profits and sales during its second quarter as renewed lockdowns and curfews continued the pandemic's home cooking trend. The Montreal-based company, which includes the Metro grocery store chain and Jean Coutu drugstores, said Wednesday it recorded a five per cent uptick in sales and a profit of $188.1 million, up from $176.2 million a year ago, for the quarter ended March 13. "We had very solid results in the second quarter ... in what can only be described as a challenging operating environment," president and CEO Eric La Fleche said during a conference call with analysts. "Our teams continue to demonstrate great dedication and resilience to serve our communities," he said. "I'm grateful for their work hard." Metro paid out $8 million of gift cards to front-line employees in the quarter, and recently announced it would be offering front-line workers another round in May ranging from $75 to $300. Redemption of the gift cards by employers has been nearly immediate, La Fleche said, noting that the gesture has been appreciated by workers. While the number of shoppers in stores — or the transaction count — remained down in the quarter, he said larger basket sizes more than offset the lower number of transactions. Overall, food same-store sales were up 5.5 per cent, the company said. Metro operates a network of supermarkets under several banners including the full-service grocery stores Metro and Metro Plus and the discount stores Super C in Quebec and Food Basics in Ontario. Meanwhile, Metro said pharmacy same-store sales were down 0.8 per cent. Restrictions on the sale of non-essential goods in Quebec combined with a much milder cold and flu season negatively impacted pharmacy sales in the second quarter, even though core prescription sales remained solid, La Fleche said. Metro has about 650 drugstores primarily under the Jean Coutu, Brunet, Metro Pharmacy and Drug Basics banners. The company said its profit amounted to 75 cents per diluted share for the quarter, up from 69 cents per share a year ago. Sales in the quarter totalled $4.19 billion, up from $3.99 billion in the second quarter of 2020. On an adjusted basis, Metro said it earned 78 cents per share for the quarter, up from an adjusted profit of 72 cents per share last year. Analysts on average had expected an adjusted profit of 76 cents per share and $4.15 billion in revenue, according to financial data firm Refinitiv. This report by The Canadian Press was first published April 21, 2021. Companies in this story: (TSX:MRU) The Canadian Press
NEW YORK — Despite thousands of years of humans working the soil, there are still things to learn. Just ask Farmer Lee Jones about the beet leaves. The Ohio-based farmer had planted too many beets and the surplus was dumped in a pile in a cooler. He returned later to find that when he dug below the first layer, to where the beets got no light exposure, beautiful leaves were growing out of the vegetable in the dark. “It’s a yellow leaf with red veins. And it’s one of the sexiest things that you can imagine,” he says. “We’re like, ‘Holy smokes, this is nicer than anything we grew on purpose!'” You might not find plants particularly sexy until you speak to Jones and catch his infectious enthusiasm for farming. He's a relentless experimenter, willing to try new techniques, new ideas and new flavours. “There are literally thousands of plants and vegetables to be explored,” he says. “We have a saying that we try and work in harmony with Mother Nature rather than trying to outsmart her.” Jones' deep knowledge about vegetables and growing them is soon available via “The Chef’s Garden: A Modern Guide to Common and Unusual Vegetables — with Recipes.” The 640-page handsome book is equal parts vegetable reference bible, family memoir and recipe collection. It comes out April 27. “We try in the book to really look for different ways to be able to utilize plants in America. We kind of think one-dimensionally,” he says. "We do bone marrow. Why can’t we do vegetable marrow?” Jones is the face of The Chef’s Garden, a sustainable, 350-acre family farm in Huron that provides chefs worldwide with seasonal specialty vegetables, microgreens, herbs and edible flowers. Name a starry chef and there's a good chance they've done business with The Chef’s Garden: José Andrés, Alain Ducasse, Daniel Boulud, Thomas Keller and Ferran Adrià, among them. With his welcoming air and signature denim bib overalls and red bow tie, Jones has become something of a celebrity, too. The Chef’s Garden grows 700 kinds of vegetables, with 150 to 200 more in trials. There's a lab where scientists analyze the soil and seeds, and there's also the Culinary Vegetable Institute, which attracts 600 visiting chefs a year to share their knowledge and cook together. Readers of the book will find new ways to prepare vegetables, from celery root to cauliflower, and learn about more unusual ingredients like carrot seeds, knotweed and radish seed pods. “For several thousand years, we always ate only the top of the carrot plant. It’s only been in the last few hundred years that we started eating the bottom of the carrot. Now nobody eats the top,” Jones says. Jones' farm is surrounded by 5,000-acre commercial farms, and he does things differently: Instead of chemicals, he uses 15 species of cover crop to replenish the soil. He argues that American farmers have lost their way regarding food and health. “I don’t knock the other farmers. They’re following the model that exists and that’s to keep the costs as low as possible and the tons per acre as high as possible. It’s not about the integrity of the plant. It’s about the tons per acre,” he says. “We’re a bunch of odd ducks out here, for sure.” Above all, Jones emphasizes taste and minimizing waste. He looks to Europeans, who learned over centuries of struggle with food insecurity to use every part of their animals. Take oxtail, a peasant food for years. “They figured out great ways to make good dishes with the flavour of the oxtail. And then Thomas Keller comes over here and puts an oxtail on a plate and it’s 90 bucks.” Jones wants to showcase vegetables, and the book offers attractive and tasty options, from Butter-Poached Squash with Hemp Seed and Coriander to Potato Pierogi with Caramelized Onion Chips. The book has a forward written by Andres and is co-written with Kristin Donnelly, with recipes by Jamie Simpson. Lucia Watson, the book's editor for Avery, says it is timely. “Vegetables are the centre of our plate more and more. And it is kind of where all of the exciting cooking is coming from — experimenting with vegetables," she says. "This gives home cooks an incredible window into that and an incredible resource. It introduces them to vegetables that they may not have heard of before, but they see at their farmer’s market and think, 'What if I brought that home? What would I do with it?' And it also makes them look at vegetables that they’ve taken for granted.” Jones got his love of farming from his dad and keeps a foot in the past — he admires what farmers before him accomplished and reveres old farm machinery — as well as embracing modern technology for things like crop analysis and distribution. “My dad had a saying that the only thing we’re trying to do is get as good as the growers were 100 years ago. It was pre-chemical, pre-synthetic fertilizer, rotating the land, rebuilding the soil,” he says. COVID-19 was a wake-up call for Jones to diversify since The Chef's Kitchen found its links to chefs and cruise lines severed when those business shuttered. The farm has since pivoted to nationwide home delivery and opened a farmer's market while it waits for restaurants to rebound. But Jones, ever the optimist, sees a silver lining even in a pandemic: There has been a surge of people interested in growing their own food and planting vegetables. “Kids emulate parents behaviour. And guess what? Parents planted gardens and kids wanted to go help. And when a kid grows a carrot and they pull it out, even if they didn’t like it before, they’re more interested in trying a carrot," he says. "So I think out of the ashes of this we have to find those good things.” ___ Online: https://www.farmerjonesfarm.com/pages/book ___ Mark Kennedy is at http://twitter.com/KennedyTwits Mark Kennedy, The Associated Press
Stocks were mostly higher in early trading Wednesday as investors continued to work through company earnings reports and closely watch the bond market. The S&P 500 index was up 0.2% after briefly starting the day in the red, as of 9:50 a.m. Eastern. The Dow Jones Industrial Average was up 0.3% and the Nasdaq Composite lost 0.1%. Netflix led a decline in communications sector stocks with a drop of 7.7%. The video streaming pioneer disappointed investors with its latest report on subscriber additions, which came in below its own forecasts. The gangbuster growth Netflix had seen during the pandemic appeared to be slowing as people start leaving their homes more and as competition from rival services picks up. Much of the market's focus over the next two weeks will be on individual companies and how well their quarterly results turn out. This week roughly 80 members of the S&P 500 are due to report results, as well as one out of every three members of the Dow. On average, analysts expect quarterly profits across the S&P 500 to climb 24% from a year earlier, according to FactSet. Investors are looking to justify the market's advance this year, despite the lingering pandemic and higher-than-normal unemployment. There are also signs of COVID infections increasing outside the U.S. in major economies such as India and Brazil once again. Big companies to report their results after Wednesday's closing bell include Chipotle Mexican Grill and Las Vegas Sands. Both companies have been heavily hit by the pandemic, as fewer Americans have travelled and eaten out at restaurants during the pandemic. The bond market was relatively quiet in early trading. The yield on the 10-year Treasury heald steady at 1.56%. The Associated Press
Grenfell resident who raised fire concerns labelled troublemaker, inquiry toldEd Daffarn complained before the disaster about fire safety flaws but was treated with ‘contempt’ Ed Daffarn’s evidence included seven complaints relating to fire safety made before the Grenfell Tower disaster. Photograph: Karen Robinson/The Observer
Toronto Maple Leafs coach Sheldon Keefe is confident Jack Campbell and David Rittich will play better in the upcoming games as they wait for Frederik Andersen to return from the injured list.
The "Mezcal Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, Product, and Sales Channel" report has been added to ResearchAndMarkets.com's offering.
Canada's main stock index opened flat on Wednesday as a drop in oil prices offset the boost from positive ...
A rundown of the sure things and no-hopers for this year’s Oscar ceremony
The U.S. Food and Drug Administration (FDA) said it had completed its inspection of a U.S. plant that makes Johnson & Johnson's COVID-19 vaccine and asked for remediation of issues including peeling paint and loose debris at the site. Emergent Biosolutions, which owns the plant, earlier this week said it would stop production of new drug material at the plant, while the FDA conducted an inspection of the facility. The FDA's inspection closeout report, also known as "FDA Form 483", cited observations including failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson and AstraZeneca.
DOJ action revives strategy of federal intervention in troubled police departments
OVERLAND PARK, Kan., April 21, 2021 (GLOBE NEWSWIRE) -- Yellow Corporation (NASDAQ: YELL) is recruiting employees for new positions in Wheeling, Illinois. On Thursday, April 29, Yellow will host a hiring event as the trucking company looks to fill jobs including dock workers and local drivers. Yellow intends to hire qualified individuals immediately for 19 jobs in Wheeling with more positions open nationwide. Yellow is the second largest less-than-truckload carrier and the fifth largest transportation company in North America. Yellow’s 30,000 employees are based in all 50 states as well as Puerto Rico, Canada and Mexico. Yellow’s Wheeling hiring event is among more than two dozen similar recruiting events taking place across America between now and July. By the end of 2021, Yellow aims to hire thousands of new employees nationwide with at least 1,500 of those positions earmarked for commercial drivers. “Seventy percent of America’s freight moves on our nation’s highways, so it’s essential that the industry continue to ramp up hiring to keep the U.S. supply chain humming along,” said Darren Hawkins, Chief Executive Officer of Yellow. “Yellow pays very competitive wages and offers outstanding healthcare benefits for employees,” said Mr. Hawkins. “For those with trucking experience or not, or folks looking for a new opportunity or needing to make a job change due to pandemic fallout, it’s an exciting time to build a career and a future at Yellow.” “Hiring is our number one priority,” said Hawkins. “Our freight professionals serve as the economic lifeline to nearly every community in America. Transportation and trucking people are patriots.” On Thursday, April 29, Yellow’s recruiting event will take place at its YRC Freight Wheeling terminal, 1000 Chaddick Drive, Wheeling, Ill. from 9:00 AM – 4:00 PM. Candidates will have the opportunity to interview with hiring managers and receive assistance with applications and paperwork. No reservation is necessary. For more information or to apply, please visit www.MyYellow.com, and click “Careers” in the top right. About Yellow CorporationYellow Corporation has one of the largest, most comprehensive logistics and less-than-truckload (LTL) networks in North America with local, regional, national, and international capabilities. Through our teams of experienced service professionals, Yellow Corporation offers industry-leading expertise in flexible supply chain solutions, ensuring customers can ship industrial, commercial, and retail goods with confidence. Yellow Corporation, headquartered in Overland Park, Kan., is the holding company for a portfolio of LTL brands including Holland, New Penn, Reddaway, and YRC Freight, as well as the logistics company HNRY Logistics. Please visit our website at www.myyellow.com for more information. Media Contacts:Mike Kelley913-696-6121mike.kelley@myyellow.comHeather Nauertheather.nauert@myyellow.com Investor Contact:Tony Carreño913-696-6108investor@myyellow.com
Abstract: - Global Throat Lozenges Market to Reach $7. 2 Billion by 2027. - Amid the COVID-19 crisis, the global market for Throat Lozenges estimated at US$5. 5 Billion in the year 2020, is projected to reach a revised size of US$7.New York, April 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Throat Lozenges Industry" - https://www.reportlinker.com/p06033130/?utm_source=GNW 2 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027. Hard Candy, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$3.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Soft segment is readjusted to a revised 3.8% CAGR for the next 7-year period. - The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 6.7% CAGR - The Throat Lozenges market in the U.S. is estimated at US$1.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2027 trailing a CAGR of 6.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 3.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR. - Compressed Segment to Record 3.5% CAGR - In the global Compressed segment, USA, Canada, Japan, China and Europe will drive the 3.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$937.4 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$955.3 Million by the year 2027, while Latin America will expand at a 3.8% CAGR through the analysis period. - Select Competitors (Total 34 Featured) - Bliss GVS Pharma Ltd.GlaxoSmithKline plcHonibe (Island Abbey Food Science Ltd.).Prestige Consumer Healthcare, Inc.Procter & Gamble CompanyReckitt Benckiser Group PlcRicola AGSanofi S.AThornton & Ross Ltd.Wm. Wrigley Jr. Company Read the full report: https://www.reportlinker.com/p06033130/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Throat Lozenges by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Throat Lozenges by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Throat Lozenges by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Hard Candy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Hard Candy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Hard Candy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Soft by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Soft by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Soft by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Compressed by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Compressed by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Compressed by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Sore Throat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Sore Throat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Sore Throat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Cough & Cold by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Cough & Cold by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Cough & Cold by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Throat Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Throat Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Throat Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 22: USA Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 25: USA Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 CANADA Table 28: Canada Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 31: Canada Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 JAPAN Table 34: Japan Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Japan Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Japan 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 37: Japan Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 CHINA Table 40: China Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: China Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: China 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 43: China Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 EUROPE Table 46: Europe Current & Future Analysis for Throat Lozenges by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 47: Europe Historic Review for Throat Lozenges by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: Europe 15-Year Perspective for Throat Lozenges by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 49: Europe Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 FRANCE Table 55: France Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: France Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: France 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 58: France Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 GERMANY Table 61: Germany Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: Germany Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: Germany 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 64: Germany Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 ITALY Table 67: Italy Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Italy Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Italy 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 70: Italy Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 73: UK Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: UK Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: UK 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 76: UK Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 SPAIN Table 79: Spain Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: Spain Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: Spain 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 82: Spain Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 RUSSIA Table 85: Russia Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Russia Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Russia 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 88: Russia Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 REST OF EUROPE Table 91: Rest of Europe Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Rest of Europe Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Rest of Europe 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 94: Rest of Europe Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 97: Asia-Pacific Current & Future Analysis for Throat Lozenges by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 98: Asia-Pacific Historic Review for Throat Lozenges by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Asia-Pacific 15-Year Perspective for Throat Lozenges by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 100: Asia-Pacific Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 AUSTRALIA Table 106: Australia Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Australia Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Australia 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 109: Australia Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 INDIA Table 112: India Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: India Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: India 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 115: India Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: India Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: India 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 SOUTH KOREA Table 118: South Korea Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: South Korea Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: South Korea 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 121: South Korea Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: South Korea Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 123: South Korea 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 124: Rest of Asia-Pacific Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 125: Rest of Asia-Pacific Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 126: Rest of Asia-Pacific 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 127: Rest of Asia-Pacific Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 128: Rest of Asia-Pacific Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 129: Rest of Asia-Pacific 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 LATIN AMERICA Table 130: Latin America Current & Future Analysis for Throat Lozenges by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 131: Latin America Historic Review for Throat Lozenges by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 132: Latin America 15-Year Perspective for Throat Lozenges by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 Table 133: Latin America Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 134: Latin America Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 135: Latin America 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 136: Latin America Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 137: Latin America Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 138: Latin America 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 ARGENTINA Table 139: Argentina Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 140: Argentina Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 141: Argentina 15-Year Perspective for Throat Lozenges by Type - Percentage Breakdown of Value Sales for Hard Candy, Soft and Compressed for the Years 2012, 2020 & 2027 Table 142: Argentina Current & Future Analysis for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 143: Argentina Historic Review for Throat Lozenges by Indication - Sore Throat, Cough & Cold and Throat Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 144: Argentina 15-Year Perspective for Throat Lozenges by Indication - Percentage Breakdown of Value Sales for Sore Throat, Cough & Cold and Throat Diseases for the Years 2012, 2020 & 2027 BRAZIL Table 145: Brazil Current & Future Analysis for Throat Lozenges by Type - Hard Candy, Soft and Compressed - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 146: Brazil Historic Review for Throat Lozenges by Type - Hard Candy, Soft and Compressed Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 147: Brazil 15-Year Perspective for Throat Lozenges by Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06033130/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001